Key Highlights: Implications: By selling the Roorkee and Noida plants (for around ₹56 crore) but retaining brands, trademarks, its Beauty Entrepreneur network, and all commercial operations, Oriflame frees up capital and management focus for sales, digital, and product innovation, yet preserves local production and supply continuity through Akums as a CDMO. For Akums, the acquisition broadens its...
Relevant Market Insights India’s biopharmaceutical sector is at a pivotal point in its evolution. Long celebrated as the world’s “pharmacy of the world” for generics and vaccines, the broader biopharma market is now defined by robust growth, expanding innovation, and compelling projections for the coming decade. Supported by strong domestic demand, favourable government policy, and...
Latest Developments in Specialty Pharma India’s pharmaceutical industry has built a global reputation as a leading supplier of affordable generic medicines. Over the past two decades, Indian companies have established strong capabilities in large-scale manufacturing, regulatory compliance, and cost-efficient drug production. However, as global competition intensifies and pricing pressures increase in traditional generics markets, many...
Summary: The Top 10 Indian Pharmaceutical Companies of 2026 demonstrate the continued strength and global competitiveness of India’s pharmaceutical sector, led by Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla. Collectively, these companies reported strong revenue performance driven by growth in specialty medicines, biosimilars, vaccines, chronic therapies, respiratory care, and global generics. While most companies...
Key Highlights: Implications: By selling the Roorkee and Noida plants (for around ₹56 crore) but retaining brands, trademarks, its Beauty Entrepreneur network, and all commercial operations, Oriflame frees up capital and management focus for sales, digital, and product innovation, yet preserves local production and supply continuity through Akums as a CDMO. For Akums, the acquisition broadens its...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two in three adults) and strengthening Novo Nordisk’s position against Lilly’s Mounjaro and generic semaglutide by adding a high-value hepatic label on the same 2.4 mg injectable dose that is...